A Phase 4 interventional study of Dextromethorphan Hydrobromide and Placebo in Cough, sponsored by Pfizer. Terminated at 18 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-04-28.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Cough with a site in United States — 17 open to participants now, 21 under way, 1 of them phase 3. Cough · United States.
Among the 103 studies in Cough with a site in United States, this one is the 26th largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2016, is one of 9 in phase 4, and was the 48th registered.
428 studies on the registry are indexed under Cough; 68 are open to participants now.
Browse Cough studies →17 of the 103 studies in Cough with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–80
Joseph C. Wu · Sites in United States
Ages 40+
University of Montana · Sites in United States
Ages 18–89 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18–89
Hyfe Inc · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Cough studies recruiting now, 20 (43%) set no upper age limit and 14 (30%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 19 · Phase 3 12 · Phase 4 9
First in 2002; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is above the median of 80 across 320 interventional studies indexed under Cough.
Median enrollment 65 across the 85 interventional studies, 65 across the 18 observational. Of the 75 that completed or were terminated, 34 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 103 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Cough — fewer than ten, so there is no comparison to draw.
6 of the studies in Cough with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05110144Mayo ClinicEfficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough | 2026-12 |
| NCT04790240All Natural Medicine Clinic, LLCMedical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) | 2026-12-30 |
| NCT06190171Vanderbilt University Medical CenterRespiratory Strength Training in Heart Transplant Recipients | 2027-02-01 |
| NCT07531901University of MontanaEvaluating the Feasibility and Reliability of Using Handheld Nebulizers to Conduct Cough Sensitivity Testing With Citric Acid | 2027-02-01 |
| NCT05273190University of MinnesotaStimulation of the Larynx to Treat Unexplained Chronic Cough | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 103 studies in Cough with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a placebo-controlled, double-blind, randomized, parallel group pilot study in approximately 150 subjects to evaluate the efficacy of dextromethorphan hydrobromide (DXM) on acute cough in a pediatric population. Subjects will be otherwise healthy males and females aged 6-11 inclusive who are experiencing acute cough as a symptom of common cold or upper respiratory tract infection. Subjects must have had onset of symptoms within 3 days of screening and qualify based on physical exam and symptom questionnaire. Eligible subjects will be given a single-blind placebo, and fitted with a cough counting device for a 2 hour run-in period. Qualifying subjects will be stratified by age and then randomized to either DXM or placebo in a 1:1 ratio and fitted with the cough recording device for the first 24 hours of treatment. Subjects will receive approximately 9 doses of investigational product over the course of the 4 day study and will complete patient reported outcome questions before the morning and afternoon doses. Subjects will return to the study site on Day 2 to remove the cough recorder and on Day 4 (+ 2 days) to complete the final visit. A review of any reported adverse events will also be completed.
This is a placebo-controlled, double-blind, randomized, parallel group pilot study in approximately 150 subjects to evaluate the efficacy of dextromethorphan hydrobromide DXM) on acute cough in a pediatric population. Subjects will be otherwise healthy males and females aged 6-11 inclusive who are experiencing acute cough as a symptom of common cold or upper respiratory tract infection. Subjects must have had onset of symptoms within 3 days of screening and qualify based on physical exam and symptom questionnaire. Eligible subjects will be given a single-blind placebo, and fitted with a cough counting device for a 2 hour run-in period. Qualifying subjects will be stratified by age and then randomized to either DXM or placebo in a 1:1 ratio and fitted with the cough recording device for the first 24 hours of treatment. Subjects will receive approximately 9 doses of investigational product over the course of the 4 day study and will complete patient reported outcome questions before the morning and afternoon doses. Subjects will return to the study site on Day 2 to remove the cough recorder and Day 4 (+2 days) to complete the final visit. A review of any reported adverse events will also be completed. Validated Patient Reported Outcomes (PRO) used in the study include morning cough assessment, afternoon cough assessment, Child Global Question, and Child Cold Symptom Checklist
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Randomization Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
Drug: Dextromethorphan Hydrobromide · Device: Cough recording device
10 mL of Placebo
Drug: Placebo · Device: Cough recording device
15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
Also known as: DXM
10 mL Placebo
FDA approved device validated for use in adults and children
Also known as: VitaloJAK
Mean of Total Cough Counts: Over 24 Hours Post-First Dose on Day 1
Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.
Time frame: Over for 24 hours post-first dose on Day 1
Mean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 1
Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.
Time frame: Between Dose 1 to Dose 2 on Day 1
Mean of Total Cough Counts: Between Dose 2 on Day 1 to Dose 3 on Day 2
Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.
Time frame: Between Dose 2 on Day 1 to Dose 3 on Day 2 (second dose of Day 1 to first dose of Day 2)
Mean of Total Cough Counts: Between Dose 3 to Dose 4 on Day 2
Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.
Time frame: Between Dose 3 to Dose 4 on Day 2 (between first and second dose of Day 2)
Mean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 1, and Between Dose 3 to Dose 4 on Day 2
Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts. In this outcome measure, as planned combined data is reported for first dosing interval (Dose 1 to Dose 2) on Day 1 and first dosing interval (Dose 3 to Dose 4) on Day 2.
Time frame: Duration between Dose 1 to Dose 2 on Day 1 (between first and second dose of Day 1) plus duration between Dose 3 to Dose 4 on Day 2 (between first and second dose of Day 2)
Mean of Total Cough Time Accumulated Over a 24-Hour Period Post-First Dose on Day 1
Time (in seconds) accumulated over a 24-hour period when cough events occurred was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated total cough time accumulated.
Time frame: Over for 24 hours post-first dose on Day 1
Change From Baseline in Morning Cough Frequency Assessed in Morning at Day 2, 3, and 4
Participants on specified time points were asked to respond to the following question: "from when you woke up this morning until now, how much have you been coughing", on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated higher frequency of cough in morning time.
Time frame: Baseline (morning screening visit on Day 1); Within 30 minutes of waking, before morning dose on Days 2, 3, and 4
Change From Baseline in Morning Cough Severity Assessed in Morning at Day 2, 3, and 4
Participants on specified time points were asked to respond to the following question: "how bad is your cough this morning", on a 5-point scale: 0= no cough, 1= a tiny bit bad, 2= a little bad, 3= bad and 4= very bad. Higher scores indicated more severe cough in morning time.
Time frame: Baseline (morning screening visit on Day 1); Within 30 minutes of waking, before morning dose on Days 2, 3, and 4
Change From Baseline in Impact of Cough on Sleep Assessed in Morning at Day 2, 3, and 4
Participants on specified time points were asked to respond to the following question: "last night in bed, how much did your cough keep you awake", on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated worse impact of cough on sleep.
Time frame: Baseline (morning screening visit on Day 1); Within 30 minutes of waking, before morning dose on Days 2, 3, and 4
Change From Baseline in Afternoon Cough Frequency Assessed at Afternoon on Day 2, 3, and 4
Participants on specified time points were asked to respond to the following question: "how much have you been coughing this afternoon" on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated higher frequency of cough in afternoon time.
Time frame: Baseline (afternoon visit on Day 1 before first dose); Before the afternoon dose on Day 2, and 3; Anytime in afternoon of Day 4
Change From Baseline in Afternoon Cough Severity Assessed at Afternoon on Day 2, 3, and 4
Participants on specified time points were asked to respond to the following question: "how bad is your cough this afternoon" on a 5-point scale: 0= no cough, 1= a tiny bit bad, 2= a little bad, 3= bad and 4= very bad. Higher scores indicated more severe cough in afternoon time.
Time frame: Baseline (afternoon visit on Day 1 before first dose); Before the afternoon dose on Day 2, and 3; Anytime in afternoon of Day 4
Change From Baseline in Child Global Question Assessed at Afternoon on Day 2, 3, and 4
Participants on specified time points were asked to respond to the following question: "how bad is your cold today", on a 5-point scale; 0= no cold, 1= a tiny bit bad, 2= a little bad, 3= bad, and 4= very bad. Higher scores indicated worse cold.
Time frame: Baseline (afternoon visit on Day 1 before first dose); Before the afternoon dose on Day 2, and 3; Anytime in afternoon of Day 4
Pediatric Global Assessment of Satisfaction With Study Medication: By Participant, and Caregiver
Participants at the end of the study were asked to respond to the following question: "How would you rate the study medication for taking away your cough?" on a 7-point scale: 0= excellent, 1= very good, 2= good, 3= fair, 4= poor, 5= very poor, and 6= terrible. Higher scores indicated poorer satisfaction with study medication. Within 20 minutes after participants completed the assessment parents/legally acceptable representative were asked to respond to the question: "How would you rate the study medication for taking away your child's cough?" on a 7-point scale: 0= excellent, 1= very good, 2= good, 3= fair, 4= poor, 5= very poor, and 6= terrible. Higher scores indicated poorer satisfaction with study medication.
Time frame: For participants: at the end of the study on Day 4; For parents/legally acceptable representatives: within 20 minutes after participant completed assessment at the end of the study on Day 4
Study was conducted in the United States from 25 February 2016 to 19 March 2020.
| Milestone | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Started | 68 | 63 |
| Treated | 68 | 63 |
| Completed | 67 | 62 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: No longer willing to participate in study | 1 | 0 |
Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.
| cough counts | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Mean of Total Cough Counts: Over 24 Hours Post-First Dose on Day 1 | 457.1 ± 367.21 | 676.8 ± 814.33 |
Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.
| cough counts | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Mean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 1 | 32.73 ± 30.597 | 47.03 ± 57.729 |
Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.
| cough counts | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Mean of Total Cough Counts: Between Dose 2 on Day 1 to Dose 3 on Day 2 | 9.70 ± 8.877 | 11.44 ± 13.193 |
Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.
| cough counts | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Mean of Total Cough Counts: Between Dose 3 to Dose 4 on Day 2 | 19.32 ± 16.752 | 33.62 ± 47.709 |
Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts. In this outcome measure, as planned combined data is reported for first dosing interval (Dose 1 to Dose 2) on Day 1 and first dosing interval (Dose 3 to Dose 4) on Day 2.
| cough counts | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Mean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 1, and Between Dose 3 to Dose 4 on Day 2 | 26.13 ± 21.498 | 40.39 ± 49.896 |
Time (in seconds) accumulated over a 24-hour period when cough events occurred was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated total cough time accumulated.
| seconds | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Mean of Total Cough Time Accumulated Over a 24-Hour Period Post-First Dose on Day 1 | 350.5 ± 268.95 | 502.7 ± 566.57 |
Participants on specified time points were asked to respond to the following question: "from when you woke up this morning until now, how much have you been coughing", on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated higher frequency of cough in morning time.
| units on a scale | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Baseline | 3.4 ± 0.65 | 3.3 ± 0.63 |
| Change at Day 2 | -1.2 ± 1.30 | -0.7 ± 1.15 |
| Change at Day 3 | -1.5 ± 1.15 | -1.1 ± 1.38 |
| Change at Day 4 | -2.0 ± 1.20 | -1.8 ± 1.40 |
Participants on specified time points were asked to respond to the following question: "how bad is your cough this morning", on a 5-point scale: 0= no cough, 1= a tiny bit bad, 2= a little bad, 3= bad and 4= very bad. Higher scores indicated more severe cough in morning time.
| units on a scale | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Baseline | 3.1 ± 0.54 | 3.1 ± 0.60 |
| Change at Day 2 | -1.1 ± 0.89 | -0.6 ± 1.19 |
| Change at Day 3 | -1.4 ± 0.96 | -1.3 ± 1.22 |
| Change at Day 4 | -1.9 ± 1.10 | -1.8 ± 1.15 |
Participants on specified time points were asked to respond to the following question: "last night in bed, how much did your cough keep you awake", on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated worse impact of cough on sleep.
| units on a scale | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Baseline | 2.8 ± 1.15 | 3.0 ± 1.19 |
| Change at Day 2 | -0.8 ± 1.56 | -0.7 ± 1.45 |
| Change at Day 3 | -1.3 ± 1.59 | -1.4 ± 1.67 |
| Change at Day 4 | -1.8 ± 1.57 | -1.9 ± 1.74 |
Participants on specified time points were asked to respond to the following question: "how much have you been coughing this afternoon" on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated higher frequency of cough in afternoon time.
| units on a scale | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Baseline | 3.2 ± 0.80 | 3.4 ± 0.73 |
| Change at Day 2 | -0.7 ± 1.25 | -0.6 ± 1.06 |
| Change at Day 3 | -1.5 ± 1.30 | -1.4 ± 1.27 |
| Change at Day 4 | -1.9 ± 1.22 | -1.8 ± 1.41 |
Participants on specified time points were asked to respond to the following question: "how bad is your cough this afternoon" on a 5-point scale: 0= no cough, 1= a tiny bit bad, 2= a little bad, 3= bad and 4= very bad. Higher scores indicated more severe cough in afternoon time.
| units on a scale | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Baseline | 2.8 ± 0.83 | 3.1 ± 0.84 |
| Change at Day 2 | -0.7 ± 1.16 | -0.6 ± 0.98 |
| Change at Day 3 | -1.4 ± 1.15 | -1.4 ± 1.24 |
| Change at Day 4 | -1.7 ± 1.08 | -1.6 ± 1.45 |
Participants on specified time points were asked to respond to the following question: "how bad is your cold today", on a 5-point scale; 0= no cold, 1= a tiny bit bad, 2= a little bad, 3= bad, and 4= very bad. Higher scores indicated worse cold.
| units on a scale | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| Baseline | 3.2 ± 0.42 | 3.3 ± 0.46 |
| Change at Day 2 | -1.1 ± 1.02 | -0.9 ± 1.01 |
| Change at Day 3 | -1.6 ± 0.93 | -1.6 ± 1.13 |
| Change at Day 4 | -2.1 ± 0.87 | -1.7 ± 1.26 |
Participants at the end of the study were asked to respond to the following question: "How would you rate the study medication for taking away your cough?" on a 7-point scale: 0= excellent, 1= very good, 2= good, 3= fair, 4= poor, 5= very poor, and 6= terrible. Higher scores indicated poorer satisfaction with study medication. Within 20 minutes after participants completed the assessment parents/legally acceptable representative were asked to respond to the question: "How would you rate the study medication for taking away your child's cough?" on a 7-point scale: 0= excellent, 1= very good, 2= good, 3= fair, 4= poor, 5= very poor, and 6= terrible. Higher scores indicated poorer satisfaction with study medication.
| units on a scale | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| By Participant: | 1.7 ± 1.20 | 1.6 ± 1.26 |
| By Caregiver: | 1.8 ± 1.07 | 1.9 ± 1.16 |
Collected over Day 1 up to 14 days after last dose of study medication (up to 18 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dextromethorphan Hydrobromide | 0/68 (0%) | 0/68 (0%) | 13/68 (19.1%) |
| Placebo | 0/63 (0%) | 0/63 (0%) | 16/63 (25.4%) |
| Event | Dextromethorphan Hydrobromide | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 1/68 | 3/63 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/68 | 3/63 |
| Nasal turbinate abnormalityRespiratory, thoracic and mediastinal disorders | 3/68 | 1/63 |
| Otitis mediaInfections and infestations | 0/68 | 2/63 |
| Upper-airway cough syndromeRespiratory, thoracic and mediastinal disorders | 0/68 | 2/63 |
| Dennie-Morgan foldSkin and subcutaneous tissue disorders | 2/68 | 0/63 |
| LymphadenopathyBlood and lymphatic system disorders | 1/68 | 1/63 |
| Lip dryGastrointestinal disorders | 0/68 | 1/63 |
| MalaiseGeneral disorders | 0/68 | 1/63 |
| BronchiolitisInfections and infestations | 0/68 | 1/63 |
The safety analysis set included all participants who received the study drug.
| Age, Continuous(Years) | Dextromethorphan Hydrobromide | Placebo | Total |
|---|---|---|---|
| Mean | 8.3 ± 1.57 | 8.0 ± 1.73 | 8.2 ± 1.65 |
| Sex: Female, Male(Participants) | Dextromethorphan Hydrobromide | Placebo | Total |
|---|---|---|---|
| Female | 35 | 32 | 67 |
| Male | 33 | 31 | 64 |
| Ethnicity (NIH/OMB)(Participants) | Dextromethorphan Hydrobromide | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 7 | 11 |
| Not Hispanic or Latino | 64 | 56 | 120 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dextromethorphan Hydrobromide | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 24 | 22 | 46 |
| White | 40 | 39 | 79 |
| More than one race | 4 | 2 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2016 to primary completion in Mar 2020, 48 months.
Results were first posted in Apr 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextromethorphan